Topics

Articles

How drugmakers can navigate the program’s pricing challenges and regulatory developments.

A 340B Navigation Guide for Pharmaceutical Manufacturers

Conditions require a disciplined approach to drug pricing.

‘Bolus’ Markets: Unique Business Opportunities with Promise and Risk

Delays could harm older Americans, interest group states.

AARP Advocates Timely Medicare Drug Price Negotiations

In what could presage a radical reshuffling of drug pricing and distribution, the insurer is dropping CVS Caremark as its PBM.

Blue Shield of California Bids to Sidestep Traditional Pharmacy Benefit Management Services 

Illinois Governor JB Pritzker signed into a law a bill prohibiting PBM retaliation against pharmacists who disclose information during government proceedings.

Illinois Governor Signs Legislation Targeting PBM Retaliation

Analysis requested by PhRMA indicates that these facilities charge anywhere from two to seven times what they originally paid. 

 Report: Hospitals Mark Up Medication Prices by 500%

. He can be reached at nsaraceno@mjhlifesciences.com.

Pharma Commerce team attends DIA's Annual Meeting for the first time.

The Voyage to Beantown

A dive into the issue of evidence gaps, plus the case for a chief access officer.

Are CEOs Getting Access Right?

While an option for financial assistance, patients should consider the challenges.

AFP Caution Flag for Patients

How the ‘fight-for-the-dollar’ is coming and likely will impact the bundled pricing of industry stakeholders.

Market Access